Related Experiment Video
Updated: Jul 8, 2025
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer
Chao Gao1,2, Xiangqin Fan1,2,3, Yanyan Liu1,2
1Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Background:
Cyclin-dependent kinase inhibitor 3 (CDKN3) has been studied in many cancers. However, the comprehensive and systematic pancancer analysis of CDKN3 genes is still lacking.
Methods:
Data were downloaded from online databases. R was used for analysis of the differential expression and gene alteration of CDKN3 and of the associations between CDKN3 expression and survival, signaling pathways, and drug sensitivity. Clinical samples and in vitro experiments were selected for verification.
Results:
CDKN3 expression was higher in most types of cancers, and this phenotype was significantly correlated with poor survival. CDKN3 showed gene alterations and copy number alterations in many cancers and associated with some immune-related pathways and factors. Drug sensitivity analysis elucidated that CDKN3 could be a useful marker for therapy selection. Clinical samples elucidated CDKN3 expressed high in endometrial cancer tissue. In vitro studies showed that CDKN3 induced pro-tumor effect in immune environment and facilitated endometrial cancer cell proliferation and G1/S phase transition.
Conclusion:
CDKN3 has been shown to be highly expressed in most types of cancers and promoted cancer cell progression. CDKN3 may serve as a novel marker in clinical diagnosis, treatment, and prognosis prediction in future.
Insights
Cyclin-dependent kinase inhibitor 3 (CDKN3) is highly expressed in most cancers, correlating with poor survival and promoting tumor progression. CDKN3 may serve as a novel biomarker for cancer diagnosis and prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Cyclin-dependent kinase inhibitor 3 (CDKN3) role is under investigation across various cancers.
- A comprehensive pancancer analysis of CDKN3 gene expression and its implications is currently lacking.
Purpose of the Study:
- To conduct a systematic pancancer analysis of CDKN3.
- To investigate the association of CDKN3 with cancer progression, survival, and therapeutic strategies.
Main Methods:
- Utilized publicly available cancer genomic data.
- Performed differential expression, gene alteration, and survival analyses using R.
- Validated findings through clinical sample analysis and in vitro experiments.
Main Results:
- CDKN3 overexpression was observed in most cancers, linked to poorer patient survival.
- CDKN3 alterations and associations with immune-related pathways were identified.
- CDKN3 expression correlated with drug sensitivity and showed a pro-tumorigenic role in endometrial cancer.
Conclusions:
- CDKN3 is frequently overexpressed in cancers, promoting tumor progression.
- CDKN3 shows potential as a biomarker for clinical diagnosis, treatment selection, and prognosis.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:39Positive Regulator Molecules
02:38Mitogens and the Cell Cycle